SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and BioAtla (NASDAQ:BCAB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Institutional and Insider Ownership
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by insiders. Comparatively, 8.4% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares SQZ Biotechnologies and BioAtla’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
BioAtla | N/A | -110.65% | -75.37% |
Risk and Volatility
Analyst Ratings
This is a summary of current ratings and recommmendations for SQZ Biotechnologies and BioAtla, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SQZ Biotechnologies | 0 | 0 | 0 | 0 | N/A |
BioAtla | 0 | 0 | 3 | 0 | 3.00 |
BioAtla has a consensus target price of $11.00, suggesting a potential upside of 354.55%. Given BioAtla’s higher probable upside, analysts plainly believe BioAtla is more favorable than SQZ Biotechnologies.
Valuation and Earnings
This table compares SQZ Biotechnologies and BioAtla’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SQZ Biotechnologies | $18.16 million | 0.08 | -$79.46 million | ($2.61) | -0.02 |
BioAtla | $250,000.00 | 452.14 | -$123.46 million | ($2.59) | -0.91 |
SQZ Biotechnologies has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
BioAtla beats SQZ Biotechnologies on 7 of the 12 factors compared between the two stocks.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About BioAtla
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.